Edition:
India

Sienna Biopharmaceuticals Inc (SNNA.OQ)

SNNA.OQ on NASDAQ Stock Exchange Global Select Market

15.93USD
19 Jul 2018
Change (% chg)

-- (--)
Prev Close
$15.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
38,895
52-wk High
$28.95
52-wk Low
$13.37

Latest Key Developments (Source: Significant Developments)

Sebacia Announces Favorable Ruling By U.S. Court Regarding Patent Proceedings With Sienna Biopharma
Monday, 7 May 2018 

May 7 (Reuters) - Sebacia Inc::SEBACIA - ANNOUNCES FAVORABLE RULING BY U.S. FEDERAL COURT REGARDING PATENT INTERFERENCE PROCEEDINGS WITH SIENNA BIOPHARMACEUTICALS INC.SEBACIA - RULING RELATES TO PATENT INTERFERENCE PROCEEDING BETWEEN GENERAL HOSPITAL CORP, OWNER OF SOME OF CO'S LICENSED PATENTS, & SIENNA BIOPHARMACEUTICALS.SEBACIA SAYS FEDERAL CIRCUIT RULED IN FAVOR OF GHC REGARDING A PATENT INTERFERENCE PROCEEDING CONCERNING SIENNA'S PATENT NO. 8,812,941.  Full Article

Sienna Biopharmaceuticals Announces First Patient Dosed In Proof-Of-Concept Trial Of Topical By Design JAK Inhibitor SNA-125 For Atopic Dermatitis
Monday, 12 Mar 2018 

March 12 (Reuters) - Sienna Biopharmaceuticals Inc ::SIENNA BIOPHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PROOF-OF-CONCEPT TRIAL OF TOPICAL BY DESIGN™ JAK INHIBITOR SNA-125 FOR ATOPIC DERMATITIS.SIENNA BIOPHARMACEUTICALS INC - ‍TOP-LINE RESULTS FROM STUDY EXPECTED IN Q4 OF 2018​.SIENNA BIOPHARMACEUTICALS INC - ‍TRIAL TO ENROLL ABOUT 30 PATIENTS WITH ATOPIC DERMATITIS​.  Full Article

Sienna Biopharmaceuticals posts qtrly loss per share $1.12‍​
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals reports third quarter 2017 financial results.Sienna Biopharmaceuticals Inc - Qtrly loss per share $1.12‍​.Sienna Biopharmaceuticals Inc - ‍Sienna's cash and cash equivalents as of Sept. 30, 2017, totaled approximately $88.6 million​.Sienna Biopharmaceuticals - ‍ Expects non-cash component related to acquisition of creabilis to continue to impact G&A expenses in future quarters​.  Full Article

Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals announces first patient dosed in phase 2B trial of topical SNA-120.Sienna Biopharmaceuticals Inc - ‍top-line results expected in first half of 2019​.Sienna Biopharmaceuticals - ‍phase 2B trial of topical SNA-120 to enroll about 190 patients with Pruritus associated with psoriasis​.  Full Article

Sienna Biopharmaceuticals announces pricing of initial public offering of common stock
Thursday, 27 Jul 2017 

July 26 (Reuters) - Sienna Biopharmaceuticals Inc :Sienna Biopharmaceuticals, Inc. announces pricing of initial public offering of common stock.Says initial public offering of 4.4 million shares of common stock at a public offering price of $15.00 per share.  Full Article

BRIEF-Sebacia Announces Favorable Ruling By U.S. Court Regarding Patent Proceedings With Sienna Biopharma

* SEBACIA - ANNOUNCES FAVORABLE RULING BY U.S. FEDERAL COURT REGARDING PATENT INTERFERENCE PROCEEDINGS WITH SIENNA BIOPHARMACEUTICALS INC